DARTMOUTH, Nova Scotia IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that company management will be attending the BIO Investor Forum to be held on October 22-23 at the Westin St. Francis, San Francisco.
BIO Investor Forum and Webcast Oct. 23 5:00 PM PST
A live webcast of this presentation will be available under Events, Webcasts and Presentations in the investors section of IMVs website and a replay will be available approximately one hour after the presentation. Afterwards, it will be available for approximately 30 days.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the FDA potentially granting accelerated regulatory approval of DPX-Survivac. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Corporation, including access to capital, the successful design and completion of clinical trials and the receipt and timely receipt of all regulatory approvals. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties and those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and annual information form Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMVs continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at on EDGAR at
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Companys proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cellsin vivo,which are aimed at generating powerful new synthetic therapeutic capabilities. IMVs lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at
Marc Jasmin, Senior Director, Investor Relations, IMV
Mrs. Delphine Davan, Director of Communications, IMV
Improving job numbers, wages will keep fuelling our love of debt
Kevin Carmichael: Debt is already growing faster than wages, a dynamic that probably isnt sustainable
U.S., China reach substantial phase one trade deal, Trump says
As part of the deal, China agrees to some agricultural concessions and the U.S. will delay a tariff increase due next week
Tourmaline to spin off royalty division a move that could inspire other natural gas companies
While Tourmaline values the deal at $775 million, analysts say the deal would have been worth more in the public market as much as $1.25 billion
From binge to bust: A Canadian oil town lines up at the food bank
Fort McMurray has become a showcase for the debt troubles many Canadians are facing